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Response to angiotensin inhibition in rats
with sustained renovascular hypertension
correlates with response to removing renal
artery stenosis
Iraklis I. Pipinos, MD, Timothy J. Nypaver, MD, Syed K. Moshin, MD,
Oscar A. Careterro, MD, and William H. Beierwaltes, PhD, Detroit, Mich.
Purpose: Sustained (late-phase) renovascular hypertension is associated with lower plas-
ma renin activity than is the early phase. It is not clear to what extent this reduced plas-
ma renin activity reflects diminished influence of the renin-angiotensin system. It also is
not clear whether this change in the character of the disease influences the effectiveness
of surgical removal of the renal artery stenosis in reversing hypertension. Using an ani-
mal model of sustained (‡ 10 weeks after renal artery clipping) two-kidney, one-clip re-
novascular hypertension, we hypothesized that the magnitude of the depressor response
to selective angiotensin II receptor blockade with losartan would reflect the influence of
the renin-angiotensin system on hypertension and enable us to predict the depressor
response to subsequent surgical removal of the clip. 
Methods: The left renal arteries of 20 male Sprague-Dawley rats weighing 150 to 200 gm
were fitted with a silver clip (0.23 mm internal diameter). Systolic blood pressure was
measured by means of tail-cuff plethysmography for 10 weeks. Rats were then given
losartan orally (30 mg/kg a day) for 1 week while blood pressure was monitored. After
an additional week to allow recovery, 13 rats underwent surgical unclipping, and seven
underwent sham repair. Blood pressure again was monitored over the final week. 
Results: All two-kidney one-clip rats had hypertension 10 weeks after clipping (mean sys-
tolic blood pressure 206 ± 10 mm Hg). Losartan decreased systolic blood pressure by
36 ± 6 mm Hg. The response was variable, ranging from 3 to 66 mm Hg, and overall
blood pressure did not normalize (170 ± 8 mm Hg). Subsequent surgical unclipping
decreased systolic blood pressure by 46 ± 9 mm Hg. Again the response was variable,
ranging from 10 to 99 mm Hg, although overall blood pressure did not normalize (164
± 7 mm Hg). The decrease in blood pressure after unclipping showed a high correlation
with the blood pressure decrease after losartan administration (r = 0.861, p < 0.001).
Resting plasma renin activity (before intervention) was 16 ± 4 ng angiotensin I per mil-
liliter per hour and was not predictive of the response to either losartan or surgical
unclipping. The rats subjected to sham operations had no statistically significant changes
in blood pressure. Histologic evaluation showed patent renal arteries without apprecia-
ble stenosis or intimal hyperplasia after removal of the clips. 
Conclusions: In sustained two-kidney, one-clip renovascular hypertension, the depressor
response to angiotensin II receptor blockade is attenuated, suggesting that late-phase
hypertension becomes increasingly angiotensin II-independent. In our model, the extent
to which sustained renovascular hypertension becomes refractory to 7 days of
angiotensin II blockade is highly predictive of the ultimate outcome of surgical repair of
renal artery stenosis. (J Vasc Surg 1998;28:167-77.)
From the Divisions of Vascular Surgery and Hypertension and
Vascular Research, Henry Ford Hospital.
Supported in part by a grant from the National Institutes of
Health, HL-46683-AO1. 
Presented at the Twenty-first Annual Meeting of the Mid-
western Vascular Surgical Society, Chicago, Ill., Sep. 11–12,
1997.
Reprint requests: Timothy J. Nypaver, MD, Division of Vascular
Surgery, Henry Ford Hospital, 2799 West Grand Blvd., Detroit,
MI 48202.
Copyright © 1998 by The Society for Vascular Surgery and
International Society for Cardiovascular Surgery, North
American Chapter.
0741-5214/98/$5.00 + 0 24/6/90257
Renovascular hypertension affects approximately
three million persons in the United States and is the
most common cause of potentially curable sec-
ondary hypertension.1,2 Despite improvements in
recognition and diagnosis, renovascular hyperten-
sion remains an enigmatic clinical problem.
Ascertaining who has renovascular hypertension and
predicting a favorable response to operative or
endovascular intervention remain imprecise.3
Although surgical intervention carries an acceptable
morbidity rate of 10% to 20% and a mortality of 2%
to 6%, the likelihood of a complete cure of athero-
sclerotic renal arterial stenosis with secondary reno-
vascular hypertension remains less than 60%.4-7
More important, as many as 20% of patients may be
exposed to the risk of operation with no derived
benefit in the control of hypertension.4-7 In this era
of increasing endovascular intervention, a more pre-
cise means of diagnosing the condition and predict-
ing the likelihood of beneficial therapeutic interven-
tion would be useful.
Renovascular hypertension begins with physical
impairment or obstruction of renal blood flow,
resulting in renal hypoperfusion.1,8 Typically this
condition is caused by either stenosis or occlusion of
the renal artery, most often from atherosclerosis or
fibromuscular dysplasia.1 Clinical data and studies in
which modifications of the classic Goldblatt two-kid-
ney, one-clip model of renovascular hypertension are
used have suggested that renovascular hypertension
appears to evolve over three distinct phases: the early
or acute phase, a transitional phase, and a chronic or
sustained late phase.9,10 The early phase depends pri-
marily on the renin-angiotensin system.9,10 Reduced
renal perfusion stimulates renin secretion through
the renal baroreceptor mechanism, leading to an
increase in plasma angiotensin II, which provokes
systemic hypertension.10,11 Plasma renin activity in
the early phase typically may become 3 to 10 times
higher than normal. In this early phase, hypertension
can be quickly and completely reversed by means of
pharmacologic inhibition of the renin-angiotensin
system or surgical repair (or unclipping) of the renal
arterial stenosis.9,12
In the second or transitional phase, angiotensin
remains elevated and in addition to its direct vaso-
constrictor effect may increase blood pressure
through activation of secondary vasoconstrictors
such as the endothelium-derived constricting factor
thromboxane-endoperoxide.13 Angiotensin II stim-
ulation of aldosterone secretion also results in sodi-
um and water retention and increased extracellular
fluid volume, which may sustain hypertension and
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secondarily suppress renin release.1 Thus the transi-
tional phase is characterized by changes away from
the predominant angiotensin dependence of the
early phase. 
The chronic or sustained late phase of renovas-
cular hypertension is characterized by secondary
structural damage to the kidneys, vasculature, and
other organs. In contrast to the early phase, the
influence of angiotensin on maintaining elevated
blood pressure in chronic renovascular hypertension
is not clear.14 Plasma renin activity returns toward
normal values, and elevated blood pressure no
longer completely or consistently responds to short-
term treatment with either angiotensin-converting
enzyme (ACE) inhibitors or the angiotensin II
antagonist saralasin, suggesting a diminished role for
angiotensin in maintaining hypertension.9,15
Hypertension is neither consistently nor predictably
reversed with repair of the stenosis or even removal
of the stenotic kidney.16,17 Thus late-phase renovas-
cular hypertension is defined as the stage at which
secondary pathologic changes develop with inconsis-
tent or absent blood pressure responses to inhibition
or blockade of the renin-angiotensin system or sur-
gical correction of renal arterial stenosis.
These observations suggest a progression from
predominantly angiotensin-dependent hypertension
to a complex disease increasingly dependent on fac-
tors other than angiotensin II and perhaps even
independent of the stenotic kidney itself. Because of
these characteristics, we hypothesized that the
response to surgical removal of discrete renal artery
stenosis would diminish as the cause transformed
from the simple angiotensin II–dependent early
phase of renovascular hypertension to the more
complex and perhaps progressively angiotensin
II–independent character evolving with this disease.
We proposed that the depressor response to 7 days
of selective angiotensin receptor blockade may be a
useful indicator of how fully the disease has evolved
from the early into the later phases, thereby making
the success of surgical repair less assured. We tested
this theory in a rat model of two-kidney, one-clip
renovascular hypertension by comparing the blood
pressure response to 7 days of constant administra-
tion of the selective angiotensin II AT-1 receptor
antagonist losartan with the blood pressure response
to subsequent surgical repair.
METHODS 
Two-kidney, one-clip renovascular hypertension
was induced in 20 male Sprague-Dawley rats.
Thirteen rats were used in the experimental proto-
col, and seven were used as controls. The control
sham protocol was identical to the experimental pro-
tocol except that the surgical procedure did not
include repair of the stenosis by means of removal of
the renal artery clip. All procedures were approved
by the institutional animal care committee of Henry
Ford Hospital. 
Study phases
Induction of unilateral renal arterial stenosis
and renovascular hypertension. Rats weighing
150 to 175 gm were anesthetized by means of injec-
tion of sodium pentobarbital (50 mg/kg Nembutal
intraperitoneally; Abbott, Abbott Park, Ill.). Body
temperature was maintained at 37° C with a heating
module (Aquamatic K-20; American Hamilton,
Cincinnati, Ohio) and blanket. Monitoring was con-
ducted until the rats awoke from anesthesia. Under
antiseptic conditions, the left renal artery was
exposed through a retroperitoneal flank incision and
carefully dissected free of the renal vein; the con-
tralateral kidney was not disturbed. A silver clip with
an internal diameter of 0.23 mm was placed around
the left renal artery, causing moderate stenosis. The
wound was closed with 3-0 silk sutures, and a mix-
ture of collodion and iodine was applied to facilitate
healing. After recovery the rats were returned to
their cages, where they were maintained for 10
weeks so that the hypertension might evolve into the
sustained late stage.9
Sustained renovascular hypertension was defined
as the development of hypertension after clipping of
the renal artery was maintained for 10 weeks or
longer. This period equaled approximately 7% of the
life span of a healthy, nondiseased rat. As each week
of life of a rat approximates 6 months of human life,
this time was believed to represent an adequately
sustained-duration model of renovascular hyperten-
sion. During this time the rats were fed standard rat
chow (22/5 rodent diet; Teklad, Bartonville, Ill.)
and tap water ad libitum. Systolic blood pressure was
monitored weekly by means of tail cuff plethysmog-
raphy with a programmed electrosphygmomanome-
ter (PE-300; Narco Biosystems, Houston, Tex., and
dual-beam oscilloscope; Tektronix, Houston, Tex.).
Hypertension was defined as sustained systolic blood
pressure of 150 mm Hg or more. 
Blood pressure response to sustained angio-
tensin II blockade with losartan. Beginning with
the eleventh week after clipping, all rats were treat-
ed with the angiotensin II receptor blocker losartan
(supplied by Merck, Rahway, N.J.). Each rat
received 30 mg/kg losartan in the drinking water
every day for 1 week.18 Blood pressure was moni-
tored with a tail cuff 12 hours after treatment was
initiated and again at 2, 3, 5, and 7 days into losar-
tan treatment.
Recovery from chronic losartan treatment.
After 1 week, losartan treatment was discontinued,
and a recovery period of 1 week allowed. On the
basis of the half-life of losartan and its active
metabolite,19 1 week was calculated to be adequate
to eliminate the influence of losartan, representing
84 half-lives of losartan and 28 half-lives of its active
metabolite.20
After the recovery period (beginning of the 13th
week after clipping), rats underwent a second sur-
vival protocol consisting of pentobarbital anesthesia,
measurement of plasma renin activity, surgical
unclipping (or sham procedure), and arterial
catheter placement. More specifically, the rats were
again anesthetized with pentobarbital (as earlier),
and a femoral vein catheter was inserted with 250 m l
of blood collected after a stabilization period of 30
to 60 minutes. The sample was collected into potas-
sium ethylene diamine tetraacetate (EDTA), separat-
ed by means of centrifugation, and frozen at –20° C
for later analysis of plasma renin activity by means of
radioimmunoassay with a Gammacoat kit (Incstar,
Stillwater, Minn.) as adapted from the original
method of Haber et al.20 Under anesthesia the rat
underwent surgical removal of the renal arterial clip. 
Surgical repair of renal arterial stenosis by
means of unclipping versus sham unclipping pro-
cedure. The renal arterial stenosis produced with
the clip was repaired by means of surgical unclipping
in 13 rats. The remaining seven rats (sham group)
underwent the identical procedure except that the
clip was manipulated but not removed. Anesthesia
and preparation were the same as earlier with the
addition of a femoral cutdown in the right hind limb
for collection of blood and direct measurement of
blood pressure. The femoral vessels were dissected,
and catheters were placed and secured in both the
artery and vein. Polyethylene 50 and polyethylene
10 tubing (Fisher Scientific, Chicago, Ill.) were used
to catheterize the vein and artery, respectively. The
venous line was used for blood sampling (as earlier),
and the arterial catheter was used to monitor blood
pressure. The arterial line was flushed with
heparinized saline solution and tunneled beneath
the skin to an exit portal between the scapulae.
Blood pressure was recorded with a Statham pres-
sure transducer (Vigo-Spectramed, Oxnard, Calif.)
connected to a Gould chart recorder (Gould, Valley
View, Ohio). 
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The clipped left renal artery was exposed by
means of reopening the left flank incision and care-
ful dissection free from the renal vein. The clip was
cleaned of scar tissue and removed, care being taken
not to traumatize the renal vessels or parenchyma.
The wound was closed, and collodion and iodine
were applied as earlier. For the seven rats subjected
to sham procedures, the same protocol was fol-
lowed, except the clip was only prepared for removal
and manipulated but neither opened nor removed.
Rats in both groups were allowed to recover with
the femoral cannula in place for at least 2 hours until
they awoke from anesthesia. Blood pressure was
recorded throughout both operation and recovery,
after which the cannulae were flushed with
heparinized saline solution and capped. Systolic
blood pressure was measured both directly with the
permanent subcutaneous femoral arterial line and
indirectly with a tail cuff once a day for the first 3
days and then once every other day for a total of 7
to 14 days. There was excellent agreement between
direct and indirect procedures. At the conclusion of
the postsurgical period, the rats were killed with an
intraperitoneal overdose of pentobarbital. The
repaired renal arteries were gently probed with poly-
ethylene 10 tubing to make sure they were patent
and no physical resistance was present at the clip site.
Renal arteries of randomly selected rats were har-
vested and subjected to histologic examination.
Segments of each renal artery taken from the clip
site and proximal to it were fixed with formalin,
embedded in paraffin, and stained with hematoxylin
and eosin. Multiple 4 to 5 m m sections were evaluat-
ed for luminal narrowing or occlusion and any
pathologic changes in the arterial wall.
Exclusion criteria
All rats had to reach a systolic blood pressure of
150 mm Hg or more to be considered to have
hypertension. On the basis of previous experience
with two-kidney, one-clip hypertension of more
than 10 weeks’ duration, rats that responded to
angiotensin blockade with an abrupt decrease in sys-
tolic blood pressure to less than normotensive levels
were excluded. This small subpopulation (six rats
not included among the 20 study animals) respond-
ed dramatically with a rapid decrease in blood pres-
sure. Unlike the situation for the rats with early-
phase angiotensin-dependent two-kidney, one-clip
hypertension given losartan, if the drug was not
immediately withdrawn from the excluded rats, they
died within 1 to 2 days. This criterion for exclusion
was established before the study began. Finally, any
rats that exhibited bleeding from the renal artery
during surgical unclipping were excluded because of
the potential effect of hemorrhage and hypovolemia
on renin secretion.
Statistical analysis
All data are presented as mean value ± 1 standard
error. The data obtained were analyzed with Sigma
Stat statistical software (Jandel, San Rafael, Calif.).
This included descriptive statistics, both paired and
unpaired Student t tests, linear regression, and
Pearson correlation as appropriate.
RESULTS
A total of 32 male Sprague-Dawley rats were ini-
tially enrolled in the study and underwent left renal
arterial clipping. Four died, presumably of complica-
tions of hypertension or malignant hypertension,
during the initial 10-week observation period. Six
were excluded because of an immediate, extreme
drop in blood pressure to hypotensive levels in
response to losartan. Of these six, three died before
losartan was withdrawn from their drinking water,
and three were immediately taken off losartan and
survived. Two more rats were excluded because of
excess bleeding at the clip site during surgical repair.
Of the 20 rats that met the study criteria, 13 under-
went successful unclipping, and 7 underwent the
sham procedure.
Results by phase
Induction of unilateral renal artery stenosis
and renovascular hypertension. Systolic blood
pressure rose continuously after clipping for 7 weeks
and then remained relatively stable (Fig. 1). All 13
rats in the experimental group had hypertension
(systolic blood pressure ‡ 150 mm Hg) by 10 weeks
after clipping. Systolic blood pressure varied from
150 to 255 mm Hg, with a mean value of 206 ± 10
mm Hg. All rats in the sham group also had hyper-
tension 10 weeks after clipping; systolic blood pres-
sure ranged from 165 to 250 mm Hg with a mean
value of 207 ± 12 mm Hg.
Blood pressure response to sustained angio-
tensin II blockade with losartan. In the experi-
mental group, the blood pressure response to 7 days
of sustained angiotensin II inhibition varied consid-
erably, and the magnitude of the response was inde-
pendent of blood pressure before losartan treatment
(blood pressure 10 weeks after renal arterial clipping
and immediately before losartan administration)
(Fig. 2). Mean systolic blood pressure dropped by 36
± 6 mm Hg, from 206 ± 10 mm Hg (10 weeks after
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clipping) to 170 ± 8 mm Hg after administration of
losartan (p < 0.001). The decrease in blood pressure
in response to losartan varied from 3 to 66 mm Hg.
The decrease in blood pressure with sustained losar-
tan treatment exhibited a bimodal pattern. There was
a relatively rapid decline over the first 12 hours of
treatment, dropping some 30 ± 9 mm Hg, followed
by a slower progressive decline over the next 2 days,
achieving a mean decrease of 36 ± 6 mm Hg by day
3 (Fig. 3). Among the group subjected to sham pro-
cedures, systolic blood pressure response also varied
with an overall systolic blood pressure decrease of 42
± 11 mm Hg (p < 0.01) to a final blood pressure of
165 ± 4 mm Hg. The individual responses varied
from 12 to 95 mm Hg. Thus rats in both experi-
mental and sham groups had similar responses to
losartan therapy. Overall, selective angiotensin block-
ade failed to restore blood pressure to previously nor-
motensive values (p < 0.004).
Recovery from 7 days of losartan treatment.
When losartan was withdrawn, systolic blood pres-
sure returned to pretreatment values. After 7 days of
recovery, mean systolic blood pressure had returned
to 210 ± 9 mm Hg for the experimental group and
214 ± 9 mm Hg for the sham group, which corre-
lated with paired pretreatment levels (r = 0.94 and
0.98, for experimental and sham groups, respective-
ly; p < 0.001).
In the experimental group, mean plasma renin
activity for anesthetized rats with two-kidney, one-clip
hypertension 12 weeks after clipping was 16 ± 4 ng
angiotensin I per milliliter per hour, and values varied
from 0.92 to 55.5 ng angiotensin I per milliliter per
hour. Plasma renin activity for the sham group was 11
± 4 ng angiotensin I per milliliter per hour, no differ-
ent from that of the experimental group.
Surgical repair of renal arterial stenosis by
means of unclipping versus sham unclipping.
Among the experimental group, surgical repair low-
ered systolic blood pressure by 46 ± 7 mm Hg (Fig.
Fig. 1. Progression of systolic blood pressure over 10
weeks after clipping of the left renal artery in 20 rats.
Fig. 2. Changes in systolic blood pressure induced by 1
week of sustained angiotensin receptor blockade by means
of losartan among 13 rats with sustained (10 to 11 weeks)
two-kidney, one-clip renovascular hypertension.
Fig. 3. Time course of the decrease in systolic blood pres-
sure over 7 days in response to sustained losartan treat-
ment and surgical repair among 13 rats with sustained
two-kidney, one-clip renovascular hypertension.
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over the next 2 days, stabilizing around a mean
blood pressure drop of 46 ± 7 mm Hg by day 3.
Results with the indwelling arterial catheter and with
the tail-cuff method correlated closely with each
other (r = 0.9, p < 0.001). Among the rats subject-
ed to sham operations, systolic blood pressure did
not change significantly during the postoperative
period. Mean blood pressure was only 3 ± 4 mm Hg
lower than (and not significantly different from) the
resting value 7 days after the procedure. 
As shown in Fig. 5, a high degree of correlation
between the blood pressure fall in response to 7 days
of losartan treatment and the decrease after surgical
repair was consistently observed (r = 0.86, p <
0.001). Thus the drop in blood pressure after 7 days
of angiotensin II inhibition proved to be a reliable
predictor of the extent to which blood pressure
would fall after surgical repair of stenosis by means of
unclipping. Plasma renin activity could not be used
to predict the blood pressure response to either
angiotensin inhibition with losartan or surgical
unclipping in these two-kidney, one-clip rats. This
finding may reflect a lack of correlation between plas-
ma renin activity and the potential reversibility of the
renovascular hypertension or the inherent variability
of plasma renin activity values among anesthetized
rats compared with conscious, unanesthetized rats. 
Histologic evaluation 
Each of the unclipped left renal arteries harvest-
ed had a patent lumen without residual narrowing at
the clip site. No pathologic abnormalities were
observed in the endothelium, elastic lamina, media,
or adventitia (Fig. 6). The only pathologic abnor-
mality observed at the clip site was evidence of non-
constricting periadventitial fibrosis, which did not
appear to compromise the vascular lumen.
DISCUSSION
We found that rats with two-kidney, one-clip
renovascular hypertension sustained over 10 to 14
weeks had near-normal rather than elevated plasma
renin activity and that most rats had an attenuated
blood pressure response to chronic selective
angiotensin receptor blockade. This suggests that
the elevated blood pressure in this sustained phase of
renovascular hypertension has become, to varying
degrees, relatively angiotensin independent, espe-
cially compared with the high angiotensin depen-
dence observed in early-phase disease. Our data also
suggest that the extent to which the hypertension
becomes refractory to an angiotensin receptor
blocker is a direct predictor of the magnitude of the
4), from 210 ± 10 mm Hg 12 weeks after clipping
to 164 ± 7 mm Hg (p < 0.001). The response to
unclipping varied from 10 to 99 mm Hg. As with
losartan administration, there was an initial rapid
drop of 45 ± 6 mm Hg over the first 24 hours after
unclipping (Fig. 3). This effect was not immediate,
however, because blood pressure fell by only 7 ± 6
mm Hg during the first 3 hours after unclipping.
The second phase of the depressor response evolved
Fig. 5. Correlation between decrease in systolic blood
pressure in response to 1 week of losartan treatment com-
pared with surgical repair by means of unclipping of renal
arterial stenosis among 13 rats with sustained two-kidney,
one-clip renovascular hypertension. 
Fig. 4. Changes in systolic blood pressure in response to
surgical repair of renal arterial stenosis among 13 rats with
sustained two-kidney, one-clip renovascular hypertension.
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blood pressure response to surgical repair of renal
arterial stenosis by means of unclipping. 
Renovascular hypertension is believed to account
for 5% to 10% of cases of hypertension. In general,
options for direct treatment include operative revas-
cularization by means of bypass or endarterectomy
or endovascular procedures such as angioplasty with
or without stent placement. As many as 20% to 40%
of patients with atherosclerosis-induced renovascular
hypertension exhibit an incomplete or even lack of a
response despite seemingly adequate repair. This
failure to improve hypertension, thereby exposing
the patient to the unnecessary risk of operation,
angioplasty, or stent placement may occur as the
result of (1) an incorrect preoperative or preproce-
dural diagnosis, (2) residual or occult renovascular
disease with renal hypoperfusion and continued acti-
vation of the renin-angiotensin system, or (3) pro-
gression to a chronic form of renovascular hyperten-
sion no longer remedial or responsive to repair of
the stenosis. The last phase has been characterized
by the potential for renal damage, vascular or
endothelial dysfunction, and normal to near-normal
renin and angiotensin levels.9,15 With sustained or
late-phase renovascular hypertension, blood pres-
sure does not respond to acute single-dose interven-
tion with ACE inhibitors or the angiotensin antago-
nist saralasin.9,15 Further, the hypertension does not
seem to be reversible with correction of the stenosis
or removal of the ischemic kidney.16,17 However,
there is considerable controversy about the character
of the so-called chronic phase. Reports have sug-
gested varying degrees of angiotensin influence on
blood pressure21,22 as well as success of surgical
intervention.23,24 Previous studies performed on
animals with sustained two-kidney, one-clip renovas-
cular hypertension revealed inconsistent responses
to either correction of the stenosis or ipsilateral
nephrectomy, in that most animals continued to
have hypertension.16,17 Other investigators noted
complete resolution of sustained renovascular hyper-
tension with either unclipping or nephrectomy,
whereas still others noted a depressor response to
unclipping alone but not to nephrectomy.22-24 Thus
the importance of the renin-angiotensin system in
sustained renovascular hypertension and, according-
ly, the relation of the renin-angiotensin system to the
outcome of surgical intervention remains unclear. 
So what is the role of the renin-angiotensin sys-
tem in the maintenance of sustained renovascular
hypertension? In all probability, there is no one sim-
ple answer, and our data and the wide range of pub-
lished results suggest a spectrum of possible levels of
influence. In this study, plasma renin activity was 16
± 4 ng angiotensin I per milliliter per hour among
anesthetized rats with chronic two-kidney, one-clip
hypertension and 11 ± 4 ng angiotensin I per milli-
liter per hour among rats with chronic two-kidney,
one-clip hypertension subjected to sham procedures.
These values are slightly but not significantly higher
than those reported previously (by W.H.B.) after
studies on barbiturate-anesthetized rats with normal
blood pressure (10 ± 3 ng angiotensin I per milliliter
per hour).25 However, the results are only 20% to
30% of plasma renin activity values for rats with
acute-phase (4 to 5 weeks) two-kidney, one-clip ren-
ovascular hypertension (51 ± 6 ng angiotensin I per
milliliter per hour; p < 0.001).12 Thus, notwithstand-
ing some variability, plasma renin activity appears to
be returning toward normal in two-kidney, one-clip
rats as they progress away from the early phase of the
disease, despite persistent hypertension. 
Fig. 6. Histologic comparison of the renal artery proximal to the clipping site (left) with the
site after surgical repair by means of unclipping.
The response to 7 days of pharmacologic angio-
tensin blockade was significant but only decreased
blood pressure to 170 ± 8 mm Hg, thus remaining
in the hypertensive range. The varying degree of the
fall in blood pressure among individual rats and the
lack of correlation or predictability between the
response to losartan and basal plasma renin activity
suggest that these two-kidney, one-clip rats 10 to 13
weeks after clipping represent a diverse population
of animals undergoing change from the angiotensin
dependence of the early and intermediate phases to
the diminished angiotensin influence seen with sus-
tained hypertension. Our data did not address the
factors or influences that replace angiotensin in sus-
taining hypertension or the source of the remaining
angiotensin. 
In general, any hypertensive state can be seen as
an inappropriate balance between the capacity of the
vascular system and the volume of fluid within it.
Therefore in sustained disease other vasoconstrictor
systems, including the central and peripheral ner-
vous systems, arachidonic acid metabolites, and
endothelin, may be overactive and synergistic with
structural abnormalities of the arterial wall, leading
to an overall increase in vascular tone. These vaso-
constrictors may interact with mechanisms function-
ing to overfill the arterial tree, such as aldosterone-
induced volume retention. The source of the
remaining angiotensin in chronic renovascular
hypertension has not been addressed. The hyperten-
sion may originate from either the stenotic kidney or
the contralateral kidney, which is unprotected and
continuously exposed to this state of hyperten-
sion.16,17,26
Importantly, we proposed that these adaptations
to sustained hypertension should be reflected by the
dissipation of angiotensin influence on blood pres-
sure. We hypothesized that changes in the role of
the kidney after 10 to 14 weeks of renovascular
hypertension among rats would compromise the
benefits of surgical repair by means of unclipping.
Because of this, we proposed that the degree to
which this surgical intervention would effectively
reverse hypertension could be predicted with the
depressor response to 7 days of angiotensin block-
ade, which would serve as an index of changes tak-
ing place in the cause of the disease. It is clear from
our data (Fig. 5) that there is a remarkable correla-
tion is between the depressor response to our proto-
col of angiotensin blockade and the effectiveness of
surgical repair by means of unclipping across a broad
range of responses. The correlation is highly signifi-
cant, and the absolute responses to losartan and
unclipping (in millimeters of mercury) are nearly
equivalent. Although our data were derived from an
animal model, without the layers of complexity often
accompanying human renovascular hypertension,
our results reinforce the doctrine that patients with
a substantial angiotensin-mediated component to
their hypertension are most likely to respond to sur-
gical therapy.
One simple explanation for the refractory
responses to unclipping would be the development
of structural changes in the artery after 13 to 14
weeks of being clipped, such that despite clip
removal, the lumen remains compromised by
retained stenosis. However, all renal arteries were dis-
sected at the end of the protocol and no gross indi-
cation of residual stenosis was found. Further, histo-
logic evaluation (Fig. 6) indicated evidence of only
nonconstricting periadventitial fibrosis that did not
compromise the vascular lumen. Thus the persistence
of renovascular hypertension after clip removal must
be ascribed to adaptations, both systemic and renal,
that took place as hypertension evolved.
In contrast to the immediate response to ACE
inhibition (30 to 60 minutes) reported for two-kid-
ney, one-clip rats with acute hypertension (4 to 5
weeks after clipping),12 the delayed depressor
response to 7 days of losartan treatment consisted of
two components—a fast phase over the first 12
hours and a slower, less pronounced phase evolving
over 2 days. Other investigators have suggested that
angiotensin II functions through two separate path-
ways: an acute vasopressor response and a chronic,
slow vasopressor response.27,28 Dickinson and
Lawrence27 first described this slowly resolving con-
strictor response to angiotensin in 1963, and subse-
quent studies have supported its existence.27-30 In
support of this, prolonged infusion of ACE
inhibitors can prevent chronic renovascular hyper-
tension29; established hypertension, although mini-
mally affected by single-dose ACE inhibitors or sar-
alasin, was partially and slowly reversed by means of
chronic administration of these agents.30 Thus con-
tinued administration of losartan (rather than a sin-
gle bolus) may be critical in eliciting a complete
biphasic response to angiotensin blockade. This slow
pressor effect may occur as the result of a neurogenic
component, increased vascular responsiveness to
vasoactive agents, or alterations in the architecture
of the vessel wall28 or the renal resistance arterioles
downstream from the stenosis. 
In the clinical setting, most patients with renovas-
cular hypertension are examined in the transitional or
late phases of the disease.31 The probability that some
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of these patients have angiotensin-independent reno-
vascular hypertension may be one reason for an
incomplete or lack of response to surgical interven-
tion.4-7 Although the beneficial effects of improved
blood pressure control, despite the continued need for
antihypertensive agents (with reduced dosage or
reduced agents) are well recognized, a reliable index
to predict the degree or absence of response would be
useful to establish preprocedural goals and to reduce
the likelihood of a complete lack of response. The
most accurate noninvasive tests in the diagnostic eval-
uation and potential surgical curability of renovascular
hypertension are those involving a single acute dose of
the ACE inhibitor captopril (the so-called captopril
test). This test is used to either stimulate renin secre-
tion (by eliminating the short-loop feedback suppres-
sion of renin by elevated angiotensin), which is then
detected peripherally, or decrease angiotensin, pro-
ducing characteristic changes in glomerular filtration
rate in both kidneys, which are then identified with
renography.3,32 Both tests are reported to have a sen-
sitivity of 60% to 80%, the latter permutation being
slightly better.33 Unfortunately, ACE also degrades
kinins, and thus captopril may potentiate the indepen-
dent depressor influence of endogenous kinin forma-
tion through stimulation of prostaglandins and nitric
oxide.3 The angiotensin antagonist saralasin has been
used more recently in the diagnosis of renovascular
hypertension. This compound, however, is also a par-
tial agonist of angiotensin, and both false-positive and
false-negative results have been reported without
marked improvement over captopril.3
Although diagnostic tests with short-term
administration of an ACE inhibitor are used exten-
sively, these tests are limited as guides to surgical
prognosis.3 Besides potentiating kinins, acute
administration of ACE inhibitors may not affect the
slow pressor component of angiotensin II.27-30 In
keeping with our results using chronic losartan
administration, it has been reported that the depres-
sor response to long-term ACE inhibition is a more
accurate predictor of surgical curability of renovas-
cular hypertension than the response to acute single-
dose tests.34,35
The important modifications in our method
include sustained week-long (rather than short-
term) use of a nonpeptide (nonagonistic) selective
angiotensin AT-1 receptor antagonist (which does
not influence ACE) that selectively blocks the effect
of angiotensin II. Nonpeptide angiotensin II recep-
tor antagonists are relatively new antihypertensive
medications. Intravenous administration of losartan
to conscious rats with normal blood pressure has no
effect on blood pressure, likely reflecting the mini-
mal role of the renin-angiotensin system in regula-
tion of blood pressure among rats with normal
blood pressure.36 Use of this pharmacologic tool
allowed us to address specifically the residual influ-
ence of angiotensin in the two-kidney, one-clip
model after 10 to 14 weeks of hypertension as a
predictive index of surgical success. Within the lim-
its of our discrete animal model, a highly significant
correlation (and thus predictability) was observed.
Although our data suggest that the blood pressure
response to long-term angiotensin II blockade can
be used to predict response to surgical management
of renovascular hypertension, further studies are
necessary to ascertain the mechanisms that underlie
the apparently angiotensin II–independent form of
renovascular hypertension. Determining the cause
of this persistent hypertension perhaps might be
used to ascertain which patient with angiotensin-
independent renovascular hypertension would be
less likely to respond to surgical or endovascular
manipulations. 
As a cautionary note, a small subset of chronic
two-kidney, one-clip rats responded to angiotensin
blockade with an immediate and dramatic fall in
blood pressure to hypotensive levels. It was notable
that these rats did not have high plasma renin activ-
ity; if losartan was not withdrawn, the rats died with-
in 3 days. Experience led to prestudy establishment
of exclusion criteria to eliminate this subgroup from
the study population. These rats perhaps represent-
ed a predominant and overwhelming angiotensin
II–mediated vasoconstrictive form of hypertension
with contralateral renal sodium and water excretion
and resultant volume depletion. Thus, with the
combination of the loss of the vasoconstrictor influ-
ence of angiotensin II and the reduction in intravas-
cular volume, the rats could not compensate and
irreversible, and often fatal, hypotension ensued.
Although we do not know what separates these rats
from those who can better compensate against the
circulating effects of angiotensin II, this may be
related to the relative level of activation of the renin-
angiotensin system or differences in vascular respon-
siveness to angiotensin II.
In summary, we found that sustained two-kidney,
one-clip renovascular hypertension in rats 10 to 14
weeks after clipping is characterized by reduced plas-
ma renin activity compared with the high levels typi-
cally observed with acute two-kidney, one-clip hyper-
tension. Second, in this sustained-duration model of
two-kidney, one-clip renovascular hypertension, the
rats exhibited an attenuated depressor response to
JOURNAL OF VASCULAR SURGERY
Volume 28, Number 1 Pipinos et al. 175
sustained angiotensin II blockade. The variability in
blood pressure response observed with 1 week of
selective angiotensin II receptor blockade correlated
with a subsequent response to surgical repair by
means of unclipping of the renal arterial stenosis. We
propose that the elevated blood pressure in this sus-
tained model of renovascular hypertension has
become, to varying degrees, relatively angiotensin
independent. The extent to which this chronic hyper-
tension becomes refractory to intervention with
angiotensin receptor blockers is a direct predictor of
the potential for success of surgical repair of renal
arterial stenosis in lowering elevated blood pressure. 
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